1
|
Zhang Q, Liu Z, Li B, Mu L, Sheng K, Xiong Y, Cheng J, Zhou J, Xiong Z, Zhou L, Jiang L, Wu J, Cai X, Zheng Y, Du W, Li Y, Zhu Y. Platinum-Loaded Cerium Oxide Capable of Repairing Neuronal Homeostasis for Cerebral Ischemia-Reperfusion Injury Therapy. Adv Healthc Mater 2024; 13:e2303027. [PMID: 38323853 DOI: 10.1002/adhm.202303027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 01/12/2024] [Indexed: 02/08/2024]
Abstract
Effective neuroprotective agents are required to prevent neurological damage caused by reactive oxygen species (ROS) generated by cerebral ischemia-reperfusion injury (CIRI) following an acute ischemic stroke. Herein, it is aimed to develop the neuroprotective agents of cerium oxide loaded with platinum clusters engineered modifications (Ptn-CeO2). The density functional theory calculations show that Ptn-CeO2 could effectively scavenge ROS, including hydroxyl radicals (·OH) and superoxide anions (·O2 -). In addition, Ptn-CeO2 exhibits the superoxide dismutase- and catalase-like enzyme activities, which is capable of scavenging hydrogen peroxide (H2O2). The in vitro studies show that Ptn-CeO2 could adjust the restoration of the mitochondrial metabolism to ROS homeostasis, rebalance cytokines, and feature high biocompatibility. The studies in mice CIRI demonstrate that Ptn-CeO2 could also restore cytokine levels, reduce cysteine aspartate-specific protease (cleaved Caspase 3) levels, and induce the polarization of microglia to M2-type macrophages, thus inhibiting the inflammatory responses. As a result, Ptn-CeO2 inhibits the reperfusion-induced neuronal apoptosis, relieves the infarct volume, reduces the neurological severity score, and improves cognitive function. Overall, these findings suggest that the prominent neuroprotective effect of the engineered Ptn-CeO2 has a significant neuroprotective effect and provides a potential therapeutic alternative for CIRI.
Collapse
Affiliation(s)
- Qiang Zhang
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Zihao Liu
- Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Bo Li
- Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Pudong District, Shanghai, 200127, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, No. 160, Pujian Road, Pudong District, Shanghai, 200127, China
| | - Liuhua Mu
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, 325001, China
- School of Physical Science, University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Kai Sheng
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Yijia Xiong
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Jiahui Cheng
- Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Pudong District, Shanghai, 200127, China
| | - Jia Zhou
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Zhi Xiong
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Lingling Zhou
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Lixian Jiang
- Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Jianrong Wu
- Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Xiaojun Cai
- Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Yuanyi Zheng
- Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Wenxian Du
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Yuehua Li
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Yueqi Zhu
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 600, Yishan Road, Xuhui District, Shanghai, 200233, China
| |
Collapse
|
2
|
Arul MR, Alahmadi I, Turro DG, Ruikar A, Abdulmalik S, Williams JT, Sanganahalli BG, Liang BT, Verma R, Kumbar SG. Fluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy. Biomater Sci 2023; 11:7856-7866. [PMID: 37902365 PMCID: PMC10697427 DOI: 10.1039/d3bm00951c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 10/18/2023] [Indexed: 10/31/2023]
Abstract
Ischemic stroke causes acute CNS injury and long-term disability, with limited treatment options such as surgical clot removal or clot-busting drugs. Neuroprotective therapies are needed to protect vulnerable brain regions. The purinergic receptor P2X4 is activated during stroke and exacerbates post-stroke damage. The chemical compound 5-(3-Bromophenyl)-1,3-dihydro-2H-Benzofuro[3,2-e]-1,4-diazepin-2-one (5BDBD) inhibits P2X4 and has shown neuroprotective effects in rodents. However, it is difficult to formulate for systemic delivery to the CNS. The current manuscript reports for the first time, the synthesis and characterization of 5BDBD PEGylated liposomal formulations and evaluates their feasibility to treat stroke in a preclinical mice model. A PEGylated liposomal formulation of 5BDBD was synthesized and characterized, with encapsulation efficacy of >80%, and release over 48 hours. In vitro and in vivo experiments with Nile red encapsulation showed cytocompatibility and CNS infiltration of nanocarriers. Administered 4 or 28 hours after stroke onset, the nanoformulation provided significant neuroprotection, reducing infarct volume by ∼50% compared to controls. It outperformed orally-administered 5BDBD with a lower dose and shorter treatment duration, suggesting precise delivery by nanoformulation improves outcomes. The fluorescent nanoformulations may serve as a platform for delivering and tracking therapeutic agents for stroke treatment.
Collapse
Affiliation(s)
- Michael R Arul
- Department of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA.
| | - Ibtihal Alahmadi
- Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA
| | | | - Aditya Ruikar
- Department of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA.
- Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA
| | - Sama Abdulmalik
- Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA
| | | | - Basavaraju G Sanganahalli
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Bruce T Liang
- Calhuan Cardiology Centre, UConn Health, Farmington, CT, USA
| | - Rajkumar Verma
- Department of Neurosciences, UConn Health, Farmington, CT, USA.
| | - Sangamesh G Kumbar
- Department of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA.
- Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA
- Department of Materials Science and Engineering, University of Connecticut, Storrs, CT, USA
| |
Collapse
|
3
|
Regnault R, Klupsch F, El-Bouazzati H, Magnez R, Le Biannic R, Leleu-Chavain N, Ahouari H, Vezin H, Millet R, Goossens JF, Thuru X, Bailly C. Novel PD-L1-Targeted Phenyl-Pyrazolone Derivatives with Antioxidant Properties. Molecules 2023; 28:molecules28083491. [PMID: 37110727 PMCID: PMC10144346 DOI: 10.3390/molecules28083491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/05/2023] [Accepted: 04/13/2023] [Indexed: 04/29/2023] Open
Abstract
Orally-active anticancer small molecules targeting the PD-1/PD-L1 immune checkpoint are actively searched. Phenyl-pyrazolone derivatives with a high affinity for PD-L1 have been designed and characterized. In addition, the phenyl-pyrazolone unit acts as a scavenger of oxygen free radicals, providing antioxidant effects. The mechanism is known for the drug edaravone (1) which is also an aldehyde-reactive molecule. The present study reports the synthesis and functional characterization of new molecules (2-5) with an improved anti-PD-L1 activity. The leading fluorinated molecule 5 emerges as a potent checkpoint inhibitor, avidly binding to PD-L1, inducing its dimerization, blocking PD-1/PD-L1 signaling mediated by phosphatase SHP-2 and reactivating the proliferation of CTLL-2 cells in the presence of PD-L1. In parallel, the compound maintains a significant antioxidant activity, characterized using electron paramagnetic resonance (EPR)-based free radical scavenging assays with the probes DPPH and DMPO. The aldehyde reactivity of the molecules was investigated using 4-hydroxynonenal (4-HNE), which is a major lipid peroxidation product. The formation of drug-HNE adducts, monitored by high resolution mass spectrometry (HRMS), was clearly identified and compared for each compound. The study leads to the selection of compound 5 and the dichlorophenyl-pyrazolone unit as a scaffold for the design of small molecule PD-L1 inhibitors endowed with antioxidant properties.
Collapse
Affiliation(s)
- Romain Regnault
- ULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, CHU Lille, University Lille, F-59000 Lille, France
| | - Frédérique Klupsch
- U1286-INFINITE-Institute for Translational Research in Inflammation, ICPAL, Inserm, University Lille, F-59000 Lille, France
| | - Hassiba El-Bouazzati
- UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Inserm, CNRS, CHU Lille, University Lille, F-59000 Lille, France
| | - Romain Magnez
- UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Inserm, CNRS, CHU Lille, University Lille, F-59000 Lille, France
| | - Raphaël Le Biannic
- U1286-INFINITE-Institute for Translational Research in Inflammation, ICPAL, Inserm, University Lille, F-59000 Lille, France
| | - Natascha Leleu-Chavain
- U1286-INFINITE-Institute for Translational Research in Inflammation, ICPAL, Inserm, University Lille, F-59000 Lille, France
| | - Hania Ahouari
- LASIRE Laboratoire Avancé de Spectroscopie pour les Intéractions la Réactivité et l'Environnement, F-59655 Villeneuve d'Ascq, France
- FR 2638-IMEC-Institut Michel-Eugène Chevreul, University Lille, F-59655 Lille, France
| | - Hervé Vezin
- LASIRE Laboratoire Avancé de Spectroscopie pour les Intéractions la Réactivité et l'Environnement, F-59655 Villeneuve d'Ascq, France
| | - Régis Millet
- U1286-INFINITE-Institute for Translational Research in Inflammation, ICPAL, Inserm, University Lille, F-59000 Lille, France
| | - Jean-François Goossens
- ULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, CHU Lille, University Lille, F-59000 Lille, France
| | - Xavier Thuru
- UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Inserm, CNRS, CHU Lille, University Lille, F-59000 Lille, France
| | - Christian Bailly
- UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Inserm, CNRS, CHU Lille, University Lille, F-59000 Lille, France
- Oncowitan, Scientific Consulting Office, Wasquehal, F-59290 Lille, France
| |
Collapse
|